104 results
Page 4 of 6
8-K
EX-1.1
a4pb2py1xsur
9 Dec 20
Entry into a Material Definitive Agreement
4:38pm
8-K
gldlz0wmhmbqm2lj
9 Dec 20
Entry into a Material Definitive Agreement
4:38pm
424B5
7zmic133ztr9 16s
9 Dec 20
Prospectus supplement for primary offering
4:02pm
424B5
x2iqhxx 8j9vg9m
7 Dec 20
Prospectus supplement for primary offering
4:10pm
8-K
p61pshwywtlfyo7a9oq6
7 Dec 20
Regulation FD Disclosure
3:45pm
8-K
EX-99.1
2dtre rqas2xa
7 Dec 20
Regulation FD Disclosure
3:45pm
8-K
q1yxcgrq
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.1
yxjmrl6w8az djv9v
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.1
r7ervvtihbpzk6h
5 Nov 20
Sutro Biopharma Reports Third Quarter 2020 Financial Results
7:05am
8-K
EX-99.1
10f mbndyac6gno05pox
6 Aug 20
Sutro Biopharma Reports Second Quarter 2020 Financial Results
7:03am
8-K
EX-1.1
7cjvn9 0vzd3dt
12 May 20
Entry into a Material Definitive Agreement
5:14pm
8-K
2d5n07
12 May 20
Entry into a Material Definitive Agreement
5:14pm
424B5
1ykhz yzhp4yjgkpm
12 May 20
Prospectus supplement for primary offering
5:02pm
8-K
EX-99.1
anqrj 0dy
11 May 20
Sutro Biopharma Reports First Quarter 2020 Financial Results
4:27pm
424B5
zy1w4t
11 May 20
Prospectus supplement for primary offering
4:12pm